Literature DB >> 14516524

Chronic Daily Headache.

James R. Couch1.   

Abstract

The therapy of chronic daily headache (CDH) is complex and involves a combination of drugs, supportive psychotherapy, nondrug therapy, "tender-loving care," and "tough love." CDH is a chronic problem with exacerbations and remissions. Patients with CDH often manifest mood disorders, and recognition and treatment of these problems is a key component of success. The use of preventative antimigraine therapy is a major component of treatment of this condition. Patients with exacerbations may need judicious short courses of medications that can produce medication-overuse headache. Patients may switch to another physician to get opiates or other pain relief medications. The patient may later realize this mistake and return to the physician. Use of patient "contracts," in which the patient agrees not to take more than a prescribed amount of restricted medication or seek it elsewhere, may be helpful. In this area, there is no standard patient or standard therapeutic regimen. The treatment plan must be individualized for each patient. Taking a little extra time to talk with patients and discuss medications, procedures, and goals and objectives may pay bigger dividends in the therapeutic relationship later in the course of treatment.

Entities:  

Year:  2003        PMID: 14516524     DOI: 10.1007/s11940-996-0015-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  31 in total

1.  Ergotamine headache.

Authors:  P G Andersson
Journal:  Headache       Date:  1975-07       Impact factor: 5.887

2.  Ergotamine tolerance in patients with migraine.

Authors:  A P FRIEDMAN; T J VON STORCH
Journal:  J Am Med Assoc       Date:  1955-03-12

3.  Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects.

Authors:  J R Couch; D K Ziegler; R Hassanein
Journal:  Neurology       Date:  1976-02       Impact factor: 9.910

Review 4.  Analgesic rebound headache.

Authors:  A M Rapoport
Journal:  Headache       Date:  1988-11       Impact factor: 5.887

5.  Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons.

Authors:  R Burstein; H Yamamura; A Malick; A M Strassman
Journal:  J Neurophysiol       Date:  1998-02       Impact factor: 2.714

6.  Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?

Authors:  K M Welch; V Nagesh; S K Aurora; N Gelman
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

7.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

8.  Paradoxical effects of frequent analgesic use.

Authors:  L Kudrow
Journal:  Adv Neurol       Date:  1982

9.  Ergotamine abuse. Do patients benefit from withdrawal?

Authors:  P Tfelt-Hansen; A Krabbe
Journal:  Cephalalgia       Date:  1981-03       Impact factor: 6.292

10.  Prophylactic Therapy for Migraine.

Authors:  Shazia Afridi; Holger Kaube
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

View more
  3 in total

1.  Rebound-withdrawal headache (medication overuse headache).

Authors:  James R Couch
Journal:  Curr Treat Options Neurol       Date:  2006-01       Impact factor: 3.598

Review 2.  The tension headache component of chronic daily headache.

Authors:  James R Couch
Journal:  Curr Pain Headache Rep       Date:  2004-12

Review 3.  The long-term prognosis of tension-type headache.

Authors:  James R Couch
Journal:  Curr Pain Headache Rep       Date:  2005-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.